Featured
Search Clinical Trials
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation (External Link)
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role:
Lead Sponsor
Completed
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (External Link)
Patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells …
Baylor Role:
Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease (External Link)
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role:
Lead Sponsor
Completed
Biologic Correlative Taxotere/AC (External Link)
Breast cancer and systemic chemotherapy: Systemic chemotherapy for operable breast cancer significantly decreases the risk of relapse and death. However, it is not possible to identify those patients at the …
Baylor Role:
Collaborator
Completed
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation (External Link)
Patients will receive cytosine arabinoside (3g/m^2) IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide (45mg/kg) will be given on Day -7 and Day …
Baylor Role:
Lead Sponsor
Completed
Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors (External Link)
All children in the study will receive Regimen 1 chemotherapy. Children whose tumor is limited to one area at the beginning of the study will go on to have radiation …
Baylor Role:
Lead Sponsor
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (External Link)
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role:
Lead Sponsor
Completed
Stem Cell Transplant to Treat Patients With Systemic Sclerosis (External Link)
Before the transplant the research participant will receive daily G-CSF (Neupogen) for 5-6 days. This medication will help to stimulate the production of white blood cells (WBC) that will be …
Baylor Role:
Lead Sponsor
Completed
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis (External Link)
To participate in this study, patients will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins …
Baylor Role:
Lead Sponsor
Completed
Intrathecal Mafosfamide (External Link)
Mafosfamide is given directly into the cerebrospinal fluid twice a week for six successive weeks. If after six weeks the disease has not shown any evidence of progression (tumor growth) …
Baylor Role:
Lead Sponsor